Literature DB >> 10475187

Acute effect of nitric oxide on Raynaud's phenomenon in scleroderma.

R R Freedman, R Girgis, M D Mayes.   

Abstract

Intra-arterial infusions of L-arginine and sodium nitroprusside significantly decreased the occurrence of laboratory-induced Raynaud's phenomenon in scleroderma patients. Raising the concentration of nitric oxide may be of therapeutic value in this population.

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10475187     DOI： 10.1016/S0140-6736(99)03557-6

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


  9 in total

1.  Oral L-arginine can reverse digital necrosis in Raynaud's phenomenon.

Authors:  Christopher M Rembold; Carlos R Ayers
Journal:  Mol Cell Biochem       Date:  2003-02       Impact factor: 3.396

2.  Current Treatment Options in Raynaud's Phenomenon.

Authors:  Sergio Generini; Angela Del Rosso; Alberto Pignone; Marco Matucci Cerinic
Journal:  Curr Treat Options Cardiovasc Med       Date:  2003-04

Review 3.  The association between systemic sclerosis, arginine and asymmetric dimethylarginine.

Authors:  Li Zhang; Ya-Nan Wan; Jiu-Hua Zhao; Yu-Jie Wang; Ying-Xin Wang; Jun-Wei Yan; Xiao-Lei Huang; Jing Wang
Journal:  Inflammation       Date:  2015-02       Impact factor: 4.092

Review 4.  The establishment and utility of a population-based registry to understand the epidemiology of systemic sclerosis.

Authors:  M D Mayes
Journal:  Curr Rheumatol Rep       Date:  2000-12       Impact factor: 4.592

5.  NRAMP1 (SLC11A1): a plausible candidate gene for systemic sclerosis (SSc) with interstitial lung involvement.

Authors:  O Ates; B Müsellim; G Ongen; A Topal-Sarikaya
Journal:  J Clin Immunol       Date:  2007-09-18       Impact factor: 8.317

Review 6.  Vascular disease in scleroderma.

Authors:  Fredrick M Wigley
Journal:  Clin Rev Allergy Immunol       Date:  2009-06       Impact factor: 8.667

7.  Design of novel β-carboline derivatives with pendant 5-bromothienyl and their evaluation as phosphodiesterase-5 inhibitors.

Authors:  Dalia S El-Gamil; Nermin S Ahmed; Bernard D Gary; Gary A Piazza; Matthias Engel; Rolf W Hartmann; Ashraf H Abadi
Journal:  Arch Pharm (Weinheim)       Date:  2013-01       Impact factor: 3.751

8.  Treatment of Raynaud's phenomenon: new insights and developments.

Authors:  Ariane L Herrick
Journal:  Curr Rheumatol Rep       Date:  2003-04       Impact factor: 4.686

9.  Effect of sildenafil on digital ulcers in systemic sclerosis: analysis from a single centre pilot study.

Authors:  Claudia S Brueckner; Mike O Becker; Thomas Kroencke; Doerte Huscher; Hans Ulrich Scherer; Margitta Worm; Gerd Burmester; Gabriela Riemekasten
Journal:  Ann Rheum Dis       Date:  2009-11-08       Impact factor: 19.103
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.